Topics
News
CME/CE
Editorial Advisory Board
Partnerships
ROSACEA PHASE III STUDY
Patients with rosacea who were treated with CollaGenex Pharmaceuticals' Periostat (doxycycline hyclate) showed continuous improvement during a 16-week Phase III trial, the firm reported. Among the 134 patients who received Periostat or placebo, Periostat-treated patients experienced a significantly greater reduction in the number of inflammatory lesions, according to a preliminary data analysis.
Related Videos
Related Content
